Биомаркери
Статии в категория "Биомаркери" - 29 публикации
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease –
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations --...
Immutep Quarterly Activities Report Q2 FY26
Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North...
SpaConTDS: A multimodal contrastive learning framework for identifying spatial domains by applying tuple disturbing strategy
Author summary Advancements in ST technologies have enabled researchers to simultaneously capture histological features, gene expression profiles, and spatial information. Unsupervised clustering of captured spots into spatial domains constitutes a fundamenta…
A 20-year-old cancer vaccine may hold the key to long-term survival
Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic disease. Scientists found their immune systems retained long-lasting memory cells primed to recognize cancer. By enhancing a key immune sign…
The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir
Author summary The persistence of long-lived HIV-infected cells in people with HIV (PWH) on antiretroviral therapy (ART) is a major obstacle to finding a cure. We hypothesised that clearance of infected cells could be enhanced by combining pro-apoptotic drugs…
Страница 2 от 5 • Общо 29 статии